Elon Musk-Owned Neuralink's Brain Implant Could Fetch Over $220M Revenue In ALS Patients By 2030, Says Ark Analyst
Portfolio Pulse from Shanthi Rexaline
Elon Musk's Neuralink could generate over $220M in revenue from its N1 brain implant for ALS patients by 2030, according to Ark Investment Management analyst Pierce Jamieson. The N1 implant and R1 surgical robot are awaiting FDA approval. The technology could transform medicine and accelerate the link between humans and artificial intelligence, Jamieson said. Neuralink recently received FDA approval to commence its first-in-human clinical trial.
October 18, 2023 | 9:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The iShares U.S. Medical Devices ETF (IHI) could be impacted by the progress of Neuralink's N1 brain implant, as it represents the broader medical devices sector.
Neuralink's progress with its N1 brain implant could have a positive impact on the broader medical devices sector, which is represented by the iShares U.S. Medical Devices ETF (IHI). If Neuralink's technology is successful, it could drive growth in the sector and potentially boost the ETF's performance.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50